CD274 and neoplasm: As results, pembrolizumab alone achieved a significantly higher OS if compared with standard chemotherapy (14.9 vs. 10.7 months, p < 0.0086) in patients whose tumor over-expresses tissue PDL-1 with a Combined Positive Score, CPS ≥ 20), but no difference in survival was shown in the CPS 1–19 subpopulation [71].The association of pembrolizumab and chemotherapy was better than standard chemotherapy (13.0 vs. 10.9 months, p < 0.03) in the Intent To Treat (ITT) population (independently from the PDL-1 expression).